Landmark trial thread🧵
This series of tweets will be about key trials studying SGLT-2 inhibitors in heart failure. While initially studied for DM, these meds were shown to improve CV outcomes in CHF patients, regardless of DM status.
#MedEd #EBM #CardioTwitter #clinicaltrials
1) DAPA-HF trial:
Among patients with a reduced EF, the risk of worsening heart failure or death from CV causes was lower among those who received dapagliflozin vs placebo.
Link: nejm.org/doi/full/10.10…
2) DELIVER trial:
Dapagliflozin reduced the combined risk of worsening heart failure or CV death in patients with heart failure and a mildly reduced or preserved EF.
Link:
nejm.org/doi/10.1056/NE…
3) EMPEROR-Reduced trial👑
Among patients with heart failure and LVEF < 40%, those in the empagliflozin group had a lower risk of CV death or hospitalization for HF than those in the placebo group, regardless of diabetes status.
Link: nejm.org/doi/full/10.10…
4) EMPEROR-Preserved trial👑
Empagliflozin reduced the combined risk of CV death or hospitalization for heart failure in patients with heart failure and a preserved EF, regardless of the presence or absence of diabetes
Link: nejm.org/doi/full/10.10…
5) SOLOIST-WHF trial:
In patients with DM and worsening HF, sotagliflozin therapy resulted in significantly fewer deaths from CV causes and hospitalizations and urgent visits for heart failure than placebo.
Link:
nejm.org/doi/full/10.10…
These trials opened up an important avenue of management for heart failure. If you know of other RCTs for SGLT-2 inhibitors in heart failure patients then please share!
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.